Health Affairs July 19, 2024
The need for improved access to effective treatment for opioid use disorders is eminently clear amid the ongoing opioid crisis, with more than 105,000 drug overdose deaths in the United States for 2022 alone. In recent years, health experts have reached scientific consensus on the effectiveness of medication for opioid use disorders (MOUD) such as buprenorphine and methadone, which may be particularly effective in combination with counseling and other therapeutic services.
Recent policy efforts have therefore focused on expanding access to buprenorphine and methadone. Just this February, the Department of Health and Human Services (HHS) announced updates to federal regulations for opioid treatment programs (OTPs). These changes—the first in more than 20 years—include expanding eligibility for patients to receive take-home...
Today's Sponsors
Today's Sponsor